Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Paxene approved for E.U. marketing; Paxoral shows positive results in phase I

July 26, 1999

Valentis initiates phase I/II trial of IL-12 gene therapy

July 26, 1999

Extremely potent cytotoxic cryptophycin analogue discovered at Lilly

July 23, 1999

CDK2-inhibitory purine derivatives with potential in cancer therapy

July 23, 1999

UBCLE: a new protein discovered at Incyte; antagonists useful for cancer, etc.

July 23, 1999

Genta's BCL-2 antisense claims allowed in U.S.

July 23, 1999

Licensing opportunity from NIH: combination chemotherapy including a VIP antagonist

July 23, 1999

Molecular modeling yields new antiestrogenic and antitumor antineoplaston A10 analogues

July 22, 1999

Antisense oligonucleotides specific for TS mRNA sequences enhance FdUrd cytotoxicity

July 22, 1999

Water-soluble antitumor camptothecins reported by Japanese labs

July 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...